Introduction
Neuroblastoma (NB) is the most common extracranial solid tumor in infants and children and accounts for 15% of cancer-related mortalities, largely due to metastatic disease progression (Maris and Matthay, 1999; Brodeur, 2003; Schwab et al., 2003) . A dismal prognosis for NB significantly correlates with tumor stage, especially since advanced-stage NB remains predominantly refractory to current multimodal therapeutic options (Maris and Matthay, 1999; Brodeur, 2003) . Poor prognostic factors in NB include >1 year of age at diagnosis, MYCN amplification, unfavorable histology and increased vascularization (Seeger et al., 1985; Brodeur, 1990; Maris and Matthay, 1999) . Of these, MYCN amplification, occurring in up to 25% of primary tumors, is considered the most important oncogenic marker, strongly correlating to advancedstage disease and treatment failure (Brodeur et al., 1984; Seeger et al., 1985) . Expression of the amplified MYCN oncogene is associated with increased proliferation and enhanced malignant potential (Raschella et al., 1991; Zaizen et al., 1993; Goodman et al., 1997; Pession et al., 1997) . We and others have recently reported that targeted knockdown of MYCN induces growth arrest and apoptosis in NB cells (Kang et al., 2006b; Nara et al., 2007) .
Highly vascular in nature, NB displays increased tumor angiogenesis, which is also related to poor patient outcomes (Meitar et al., 1996) . Not surprisingly, MYCN amplification correlates with enhanced angiogenic capability in human NB tissue biopsies and cell lines (Ribatti et al., 2002) . In addition, overexpression of MYCN has been shown to downregulate inhibitors of angiogenesis (Fotsis et al., 1999; Hatzi et al., 2000) . Vascular endothelial growth factor (VEGF) is an important mediator of vascularization in NB and its expression is associated with unfavorable histology and increased aggressive behavior (Langer et al., 2000; Fukuzawa et al., 2002) . Regulation of VEGF expression involves multiple oncogenic pathways including the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. The PI3K/Akt pathway is a potent regulator of angiogenesis in both normal and cancer tissues (Hamada et al., 2005; Hennessy et al., 2005) ; mammalian target of rapamycin (mTOR) is one of the downstream effectors of this process (Tan et al., 2004; Nakamura et al., 2006) . Recently, activated Akt, the critical mediator of PI3K, has been shown to be a prognostic indicator of poor outcome in patients with NB (Opel et al., 2007) and was found to be specifically associated with late-stage and high-grade tumors. Furthermore, PI3K can regulate N-myc protein stabilization in NB cells (Chesler et al., 2006) . However, it is unclear whether the PI3K pathway and N-myc collaborate to regulate angiogenesis in NB.
In this study, we demonstrate that PI3K inhibition with chemical inhibitors (LY294002 or wortmannin) or phosphatase and tensin homolog (PTEN) adenovirus blocks VEGF expression and secretion. For the first time, we provide evidence that PI3K regulates VEGF via MYCN-dependent mechanisms. N-myc represents a critical target for VEGF regulation; therefore, MYCN amplification may play an essential role in regulating PI3K-stimulated VEGF levels in NB cells. Importantly, our findings suggest a distinct functional relationship between two major indicators of NB prognosis-N-myc and Akt activation-and their role in directing critical angiogenic pathways.
Results
Inhibition of PI3K decreases NB xenograft growth and angiogenesis in vivo PI3K inhibition has been shown to reduce tumor growth of murine NB (Chesler et al., 2006) . To determine the effects of PI3K inhibition on the angiogenic capacity of human NB in vivo, we used wortmannin, a selective inhibitor of PI3K that binds to the catalytic subunit p110 (Powis et al., 1994; Oikawa and Shimamura, 1996) . Athymic nude mice with established SK-N-SH xenografts were treated with intraperitoneal (i.p.) injections of wortmannin or ethanol vehicle for 23 days. Phosphorylated (p)-Akt was effectively suppressed (P ¼ 0.003) while total Akt levels remained constant, verifying the selectivity of wortmannin (Figure 1c ). In fact, the inhibitory effects of wortmannin in vivo were observed as early as 0.5 h following injection (Supplementary Figure 1 ). As shown in Figure 1a , there was a significant reduction in tumor volume by 43% (left) and tumor weight by 50% (right) in mice treated with wortmannin in comparison to vehicle controls. Since the growth of transplanted tumors largely depends on the angiogenic capacity of the tumor (Kang et al., 2007) , we examined tumor angiogenesis by immunohistochemical staining using VEGF and platelet/endothelial cell adhesion molecule-1 (PECAM-1) antibodies. Wortmannin administration decreased VEGF expression and endothelial components of NB xenograft vasculature when compared to controls (Figure 1b, left) . A significant decrease in intratumoral microvessel density (IMD), assessed by the quantification of PECAM-1 staining, was observed in tumors from the wortmannintreated group when compared to the control group (100, control group vs 73.7, wortmannin group) (Figure 1b,  right) . In addition, VEGF expression was lower in the wortmannin-treated group relative to the control group (P ¼ 0.08). PI3K inhibition also decreased circulating plasma VEGF concentrations compared to control levels ( Figure 1d) . Collectively, these data show that PI3K blockade affects VEGF expression and arrests growth of established human NB tumors in vivo.
PI3K/mTOR pathway regulates VEGF expression and secretion through HIF-1a in NB cells Since wortmannin treatment decreased VEGF expression in mice bearing NB xenografts, we next wanted to (Figure 2b ). This effect also correlated with a reduction of VEGF secretion into the culture media ( Figure 2c ). We further investigated the role of PI3K in NB angiogenesis by specific inhibition of its catalytic subunit p110a with siRNA (sip110a). Compared to the control (siNTC) group, sip110a treatment significantly reduced p110a mRNA and protein levels in all four cell lines (Supplementary Figure 2B) . We also found decreased VEGF secretion in sip110a-transfected cells when compared to siNTC-transfected cells (Supplementary Figure 2A) . Taken together, these results show that PI3K regulates VEGF expression at both the mRNA and protein levels in NB cells. It has previously been established that activation of PI3K/Akt by growth factors, including insulin-like growth factor (IGF)-1, leads to the phosphorylation of mTOR and induces hypoxia-inducible factor 1a (HIF-1a)-initiated VEGF transcription in NB cells (Beppu et al., 2005; Nakamura et al., 2006) . As expected, IGF-1 stimulated phosphorylation of Akt and mTOR and increased HIF-1a expression with concurrent secretion of VEGF into medium in SK-N-SH and BE(2)-C cells; this effect was abrogated by LY294002 (Figures 3a and b) . Rapamycin, the selective inhibitor of mTOR, also downregulated HIF-1a protein levels and inhibited VEGF secretion in JF and LAN-1 cells, but its inhibition was not significant in SK-N-SH and BE(2)-C cells (Figure 3c ). Interestingly, rapamycin significantly inhibited IGF-1-stimulated VEGF secretion in all four NB cell lines under IGF-1 stimulation. These data suggest that PI3K regulates other angiogenic mechanisms in NB cells, in addition to the mTORdependent pathway.
PI3K inhibition regulates IGF-1-mediated N-myc and VEGF expression
Recently, PI3K inhibition has been shown to induce N-myc degradation (Chesler et al., 2006) . N-myc overexpression, an important determinant of NB prognosis, is associated with vascularization in NB (Meitar et al., 1996; Ribatti et al., 2002) . Therefore, we next wanted to explore whether PI3K interacts with N-myc to regulate angiogenic pathways. To confirm whether PI3K regulates N-myc, MYCN-amplified BE(2)-C cells were serum-starved, treated with IGF-1 and/or LY294002, and the levels of N-myc protein were assessed. There was an upregulation of N-myc expression after IGF-1 stimulation in BE(2)-C cells. LY294002 treatment reduced N-myc expression in both the absence and presence of IGF-1 (Figure 4a ). To further confirm the mechanism involved in this process, we transiently overexpressed PTEN, the negative regulator of the PI3K/Akt pathway, using adenovirus infection in BE (2) 
N-myc expression regulates VEGF secretion in NB cells
We then wanted to investigate whether specific inhibition of N-myc could regulate VEGF expression. BE(2)-C and IMR-32 cells were transfected with siRNA against MYCN (siMYCN) for 72 h and VEGF secretion into the medium was assessed. As shown in Figure 4c , siMYCN significantly decreased VEGF expression along with N-myc expression in MYCN-amplified BE(2)-C and IMR-32 cells. In contrast, MYCN-unamplified SK-N-SH did not show any difference in VEGF secretion after transfection when compared to siNTC-transfected cells; N-myc expression was also undetectable (Figure 4c ). To confirm the specificity of the siRNA, we assessed the effects of two separate single sequences (siMYCN1 and siMYCN2); both were able to establish sufficient knockdown of N-myc (Supplementary Figure 3) .
For the purpose of verifying the role of N-myc, we transfected MYCN-unamplified SK-N-SH cells with an MYCN expression vector, which strongly upregulated N-myc mRNA and protein expression (Figure 5a , bottom). This increase in N-myc expression caused a significant increase in VEGF secretion, in contrast to cells transfected with the control vector (Figure 5a, top) . We further confirmed that these effects were dependent however, the inhibitory effects of siMYCN on VEGF secretion were enhanced when combined with rapamycin treatment in MYCN-amplified cells (Figure 6b ). Treatment with siMYCN facilitated rapamycin inhibition of IGF-1-stimulated VEGF secretion to a lesser extent in SK-N-SH cells. These data further confirm the findings that N-myc is a downstream target of PI3K, in the context of VEGF regulation, and may act in conjunction with mTOR activation.
Discussion
Aggressive progression of NB significantly correlates with the degree of tumor vascularity (Meitar et al., 1996; Ribatti et al., 2002) ; and in particular, this progression is marked by increased levels of the angiogenic marker VEGF (Fukuzawa et al., 2002) . The PI3K/Akt pathway is a crucial regulator of angiogenesis (Hamada et al., 2005) and increased activity has been determined to be a portent of poor prognosis in NB (Opel et al., 2007) . Malignant, high-grade tumors are frequently characterized by amplification of the MYCN oncogene (Meitar et al., 1996; Ribatti et al., 2002) , which is present in 30% of advanced-stage tumors (Brodeur, 2003) . In this study, we sought to evaluate the importance of N-myc in PI3K-mediated VEGF expression in NB. We identified strong expression of VEGF protein in control tumors in vivo and detected systemic levels of VEGF in nude mice, in contrast to mice treated with wortmannin. The inhibition of PI3K-mediated VEGF expression was further confirmed in vitro, further verifying the essential role of the PI3K pathway in regulating angiogenesis in NB. We also found that PI3K activation increased N-myc protein levels; this PI3K-induced N-myc stabilization was associated with an increase in VEGF secretion. Our findings strongly suggest that PI3K/Akt activation and MYCN, two factors associated with poor outcome in NB, contribute to the vascularity of NB and, therefore, may be ideal targets for NB treatment strategies. Our results further establish that PI3K/Akt acts through mTOR and HIF-1a to regulate VEGF in NB. However, we noted that in all of our cell lines, rapamycin-induced inhibition of VEGF was significant only in the presence of IGF-1. Recently, Kurmasheva et al. (2007) postulated that VEGF expression in unstimulated NB cells depends on PI3K/Akt-driven signaling that most likely bypasses mTOR. They observed that HIF-1a and VEGF expression was strongly decreased with an Akt inhibitor, but was inadequately affected by rapamycin treatment in standard (10%) serum conditions. Furthermore, in another study, Akt siRNA, but not rapamycin or mTOR siRNA, inhibited HIF-1a expression in glioblastoma and prostate cancer cells maintained in 10% serum conditions (Pore et al., 2006) . However, in that particular study, rapamycin inhibition of HIF-1a could be achieved in the presence of lower serum concentrations. This corresponds with our findings in some of our NB cells, since the rapamycin studies were carried out in serum-free conditions. The mechanism is still unclear; however, it is likely that mTOR contributes more significantly to PI3K-mediated angiogenesis in the context of nutrient depletion. Furthermore, PI3K stimulation by growth factors, such as IGF-1, may enhance the sensitivity of the mTOR/VEGF pathway to rapamycin.
Our study further identifies N-myc as a key mediator of PI3K-regulated VEGF expression in NB. PI3K activation was first shown to regulate N-myc in cerebellar neuronal precursors by stabilizing N-myc steady-state levels through GSK-3b inhibition (Kenney et al., 2004) . This observation was also noted in NB cells where LY294002 destabilized N-myc protein in a GSK3b-dependent manner (Chesler et al., 2006) . Our results, using PTEN overexpression or LY294002, corroborate the significance of PI3K regulation on N-myc expression. Moreover, simultaneous inhibition of N-myc and mTOR resulted in cooperative downregulation of VEGF secretion, suggesting that PI3K stimulation of N-myc expression and mTOR activation may be independent of each other. In fact, we observed that rapamycin had no effect on IGF-1-induced N-myc levels in NB cells; this corroborates work reported by Misawa et al. (2003) . Therefore, we have identified, for the first time, that N-myc is a novel effector of PI3K-mediated VEGF expression in NB and may operate through pathways distinct from mTOR ( Figure 7 ). If these pathways are indeed separate, we postulate that under normal or nutrient-depleted growth conditions, PI3K can regulate N-myc to induce VEGF expression; however, it is possible that PI3K may subsequently activate mTOR as a failsafe for angiogenic permanence in the absence of adequate nourishment.
Although N-myc expression has been shown to downregulate inhibitors of angiogenesis (Hatzi et al., , its function in VEGF-mediated angiogenesis is relatively unknown. On the other hand, C-myc, another member of the MYC oncogene family, is an important regulator of angiogenesis in developmental and tumor tissues, and is positively associated with VEGF expression (Baudino et al., 2002; Dews et al., 2006; von Rahden et al., 2006) . Here, we report that MYCN silencing effectively blocked VEGF expression in MYCN-amplified cell lines, regardless of serum conditions. Whereas, in low N-myc-expressing cells, MYCN knockdown could only attenuate VEGF levels subsequent to MYCN overexpression or IGF-1 stimulation. Therefore, N-myc functions as a crucial regulator of VEGF in an expression-dependent manner, indicating another role for N-myc in NB angiogenesis. Moreover, it appears that mechanisms that increase N-myc stability, such as PI3K activation, are also susceptible to inhibitors of N-myc expression.
In conclusion, our findings suggest that predictors of an unfavorable prognosis in NB, N-myc and PI3K/Akt activation, may have more than a coincidental relationship and may in fact be interdependent. Further studies will be necessary to delineate the molecular mechanisms of PI3K/N-myc/VEGF regulation of angiogenesis. These results are of clinical relevance to NB because, as heterogeneous tumors, multiple therapeutic targets will be required to effectively deter tumor progression and improve the survival rate in advanced, highly vascularized NB. Cell culture, siRNA transfection and adenovirus infection Human NB cell lines, SK-N-SH, BE(2)-C and IMR-32, were purchased from American Type Culture Collection (Manassas, VA, USA). JF, a primary NB cell line, was a gift from Dr JM Shohet (Baylor College of Medicine, Houston, TX, USA) and LAN-1 was a gift from Dr RC Seeger (University of Southern California, Los Angeles, CA, USA). Cells were grown in RPMI 1640 or Eagle's minimal essential medium with 10% fetal bovine serum (FBS) and maintained at 37 1C in a humidified atmosphere of 95% air and 5% CO 2 . For siRNA or plasmid transfection assays, 2-5 Â 10 5 cells per well were transfected with Lipofectamine 2000 as previously described (Kang et al., 2006b) . The sequences for siMYCN were GAAGAAAUCGACGUGGUCAUU(5 0 -PUGACCACGUC GAUUUCUUCUU), GAGAGGACACCCUGAGCGAUU (5 0 -PUCGCUCAGGGUGUCCUCUCUU), GAACCCAGA CCUCGAGUUUUU(5 0 -PAAACUCGAGGUCUGGGUUC UU), and GGACAGUGAGCGUCGCAGAUU(5 0 -PUCUGC GACGCUCACUGUCCUU). Cells were harvested for qRT-PCR, VEGF ELISA or western blot at indicated times. For IGF-1 studies, the attached cells were serum-starved for 24 h and treated with IGF-1 alone or in combination with inhibitors. The concentrations of IGF-1, LY294002, wortmannin, rapamycin and dimethylsulfoxide (DMSO) were 100 nM, 20mM, 500 and 50 nM, and 0.1%, respectively. Adenovirus infection was performed according to the manufacturer's instructions. Briefly, recombinant Ad-PTEN or Ad-Luc was diluted in cell culture media containing 2% FBS and added to subconfluent cells in six-well plates for 6 h at a multiplicity of infection of 40. The medium was then replaced and the cells were incubated for 18 h.
Materials and methods

Reagents
RNA isolation and real time qRT-PCR
Total cellular RNA extraction and real time qRT-PCR were carried out as previously described (Kang et al., 2006b (Kang et al., , 2007 . Briefly, we used Applied Biosystems (Foster City, CA, USA) assays-on-demand 20 Â assay mix of primers and TaqMan MGB probes (FAM dye-labeled) for the target genes, human VEGF (NM_003376, Hs00173626_m1), MYCN (NM_005378, Hs00232074_m1) and predeveloped 18S rRNA (VIC dyelabeled probe) TaqMan assay reagent (P/N 4319413E) for endogenous control. For relative quantitation of gene expression, separate tubes (singleplex) one-step RT-PCR was performed with 80 ng RNA for both target genes and endogenous control. The reagent we used was TaqMan One-Step RT-PCR Master Mix Reagent Kit (P/N 4309169). The cycling parameters for one-step RT-PCR was reverse transcription 48 1C for 30 min, AmpliTaq activation 95 1C for 10 min, denaturation 95 1C for 15 s and annealing/extension 60 1C for 1 min (repeat 40 times) on ABI7000. Duplicate C T Figure 7 Proposed mechanism of phosphatidylinositol 3-kinase (PI3K) and N-myc regulation of vascular endothelial growth factor (VEGF)/angiogenesis. N-myc regulates PI3K-mediated VEGF expression J Kang et al values were analysed in Microsoft Excel using the comparative C T (DDC T ) method as described by the manufacturer (Applied Biosystems). The amount of target (DDC T ) was obtained by normalization to an endogenous reference (18 s) and relative to a calibrator (one of the experimental samples).
Xenograft studies
Male athymic nude mice (4 to 6-weeks old) were obtained from Harlan Sprague Dawley (Indianapolis, IN, USA) . All studies were approved by the Institutional Animal Care and Use Committee at the University of Texas Medical Branch.
Mice were anesthetized and xenografts were established by subcutaneous injection of 10 Â 10 6 SK-N-SH cells per 100 ml HBSS into the bilateral flanks using a 26-gauge needle. After 34 days, the mice were randomized into two experimental groups (n ¼ 5 per group): control (vehicle; 5% ethanol in saline) and wortmannin (1.5 mg kg À1 per day; 5% ethanol in saline). All injections were administered i.p. every 12 h. Tumor growth was assessed bi-weekly by measuring the two greatest perpendicular tumor dimensions with vernier calipers (Mitutoyo, Tokyo, Japan) and body weights were recorded weekly. The tumor volumes were calculated as follows: tumor volume (mm 3 ) ¼ (tumor length (mm) Â tumor width (mm) 2 )/2. At killing, tumors and organs were excised, weighed and snap frozen in liquid nitrogen for storage at À80 1C for further assays; plasma was collected for ELISA.
Immunoblotting Whole-cell lysates or tissues were prepared as described previously (Kang et al., 2006a (Kang et al., , 2007 . Briefly, total protein was resolved on Bis-Tris gels and electrophoretically transferred to polyvinylidene difluoride membranes. Target proteins were detected by using rabbit or mouse antihuman antibodies (1:200-1000 dilutions). The membranes were washed and incubated with secondary antibodies (1:5000 dilution) conjugated with HRP. Immune complexes were visualized using the enhanced chemiluminescence system. Equal protein loading was confirmed by blotting the same membrane with b-actin antibody.
Immunohistochemistry
For VEGF staining, xenografts were fixed in formalin overnight and embedded in paraffin wax. Tumor sections (5 mm) were mounted on glass slides and staining was performed as previously described (Kang et al., 2007) . For PECAM-1 staining, frozen NB xenografts were embedded in OCT compound, mounted (5 mm) on slides, fixed by immersion in cold acetone for 2 min at À20 1C, and then air dried. Slides were washed with phosphate-buffered saline (PBS), incubated in 3% H 2 O 2 solution in methanol for 10 min and then washed with PBS. Sections were incubated with primary antibody (1:100 dilution) overnight at 4 1C, washed and incubated with biotinylated anti-immunoglobulin secondary antibody (1:50) followed by incubation with streptavidin-HRP for 30 min at room temperature. Sections were developed with diaminobenzidine reagent and the reaction was terminated by immersing slides in dH 2 O. Slides were then dehydrated, mounted and left to dry.
VEGF ELISA
For in vitro studies, the supernatant from cultured cells was collected at the indicated time points. For in vivo studies, blood was collected with EDTA to prevent coagulation, centrifuged at 2 Â 10 3 r.p.m. at room temperature for 15 min, and plasma stored at À80 1C. For assay, samples were thawed, centrifuged and VEGF levels were measured using human VEGF ELISA kit according to the manufacturer's instructions. All experiments were performed on at least two separate occasions.
Statistical analyses
Tumor size and body weight were analysed using analysis of variance (ANOVA) for a two-factor experiment with repeated measures on time in SK-N-SH in vivo experiments. All effects were assessed at the 0.05 level of significance and all interactions of the effects were assessed at the 0.15 level of significance as the experiment-wise error rates. Fisher's least significant difference procedure was used for multiple comparisons with 0.005 as the comparison-wise error rate. Data analysis was conducted using PROC MIXED with LSMEANS option and Satterthwaite approximation for the denominator degrees of freedom in SAS, Release 9.1 (SAS Institute Inc., Cary, NC, USA). IMD was captured using ImageJ software (NIH) and quantitated by analysing 18 random fields from all samples (n ¼ 5 mice per group). ImageJ was also used to perform the densitometric analysis of in vivo protein expression from immunoblots. For tumor mass and in vitro studies, statistical analyses were performed using one-way ANOVA for comparisons between the treatment groups. A P-value o0.05 was considered significant.
